The battle against the covid-19 virus is far from over. In the process, I believe that the development of vaccines is the most concerned issue. First, I would like to share with you two good news about the covid-19 vaccine:
On July 28, the Jiangsu Provincial Center for Disease Control and Prevention announced that Fosun Pharma had successfully vaccinated the first batch of 36 volunteers in the Phase I clinical trial of the covid-19 virus mRNA vaccine authorized by BioNTech in Germany. The Phase I clinical trial of the vaccine is in charge of the Jiangsu Provincial Center for Disease Control and Prevention, with the participation of Taizhou Disease Control Center and Taizhou People's Hospital.
At the same time, our global partners BioNTech and Pfizer also announced yesterday that the covid-19 mRNA vaccine BNT162b2, which has obtained the fast-track qualification granted by the US FDA, has officially launched a global phase 2/3 clinical study.
These important milestones in the research and development process have made us very excited. We also look forward to the successful completion of clinical trials, and vaccines in China can be launched globally at the same time as Germany and the United States. Vaccines are our ultimate weapon in defeating the covid-19 virus and epidemic, and they pin the hope of all mankind. Vaccine research and development has long been more than just a competition between biotech companies in research and development capabilities. I think it is a test of whether all mankind can unite and work together. The vaccine development process is full of unknowns and uncertainties. In the face of the virus, complaining to each other is meaningless, and cooperation is the only way to solve the problem. The reason why we carry out international R&D cooperation and market development is to bring better, faster, cheaper and more humane products to patients. I would also like to thank the China Medical Products Administration, the German Ministry of Health, the vaccine approval agency, and the US FDA for vaccine approval agencies in various countries for their high efficiency and decisive execution during the special period. Although the covid-19 epidemic has brought many problems to the world, the cooperation and innovation of all mankind has given us hope to solve the problem. Only by working together can we benefit the health of all mankind.
Through this epidemic, Fosun's future strategic development goals with innovation as its core have been further clarified. Innovation has always been the main battlefield for our strategic development. Today, we also received good news from Fuhong Henlius. As a leading company in the field of innovative drugs in China, the company’s second product, HLX02, was officially approved by the European Commission and became the first to enter the European market. The "Chinese nationality" monoclonal antibody biosimilars set a precedent for Chinese pharmaceutical companies to participate in the "World Cup" competition of monoclonal antibody biosimilars. As a major product under Fosun, HLX02 will represent an international-quality biological drug produced in China, serving more HER-positive breast and gastric cancer patients worldwide. What makes me even more gratified is that, in addition to being the first "Chinese nationality" monoclonal antibody biosimilar to enter the European market, HLX02 is also expected to be launched in China this year, becoming the first trastuzumab approved for marketing in China. National health and well-being.
In the future, I look forward to Fosun’s classmates making persistent efforts, continuous innovation, continuous progress, and using more international quality products to benefit more families around the world. We will also invest more resources in the field of technological innovation, cooperate with more top teams around the world, and work together for the health, happiness and prosperity of all mankind!
0 Comments